Clinical trial
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants
NCT00475033 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00475033 |
|---|---|
| Title | Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants |
| Official title | A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Canada |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Vaccines, Pneumococcal Conjugate Vaccine |
| Intervention type | Biological |
| Interventions | 13-valent Pneumococcal Conjugate Vaccine, 7-valent pneumococcal conjugate vaccine |
| Enrollment | 603 |
| Start date | Jun 1, 2007 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | May 17, 2007 |
| Last update posted | Apr 21, 2011 |
| Countries | Canada |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: